OBJECTIVES: Pramipexole, Rasagiline, and Ropinirole are approved for monotherapy in early PD. Understanding the comparative safety profiles of these products can be important information to choose an optimal therapy. As no direct comparisons of the safety profile of these products are available, our objective was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs).   METHODS: Articles were selected and reviewed via Cochrane Guidelines. Placebo-controlled randomized clinical trials were eligible for review.  Data collected for analysis included total AEs, Cognitive, Gastrointestinal (GI), and Sleep/Fatigue AE categories and dropout rates.  We used indirect meta-analysis to calculate the pooled Relative Risk (RR) of each product against placebo, and then used pairwise comparisons. Frequentist and Bayesian methods were used to compare sensitivity of findings.  RESULTS: 208 studies were identified and reviewed, 6 were determined eligible via established criterion.  The RRs and [95%CIs] from the fixed-effects model for Rasagiline, Pramipexole, and Ropinirole respectively were total AEs: .97 [.87, 1.07], 1.05 [1.00, 1.1], 1.07 [1.00, 1.14]; Cognitive: .78 [.43, 1.44], 5.56 [2.35, 13.13], 1.56 [.83, 2.94]; GI: .9 [.49, 1.63], 2.00 [1.57, 2.53], 2.43 [1.81, 3.27]; Sleep/Fatigue: .84 [.53, 1.35], 1.63 [1.35, 1.97], 3.24 [2.08, 5.05]; and DR: .60 [.39, .91], 1.01 [.66, 1.56], 1.77 [1.14, 2.76]. AEs were no worse than placebo for all Rasagiline AEs and for Ropinirole cognitive AEs. DRs for Rasagiline were significantly lower than placebo. Rasagiline had the lowest RRs with ≥ 90% confidence for all categories. Results were comparable across statistical models tested.  CONCLUSIONS: This indirect treatment comparison suggests that subjects with early PD treated with Rasagiline have less risk for adverse events and treatment dropouts than patients treated with Pramipexole or Ropinirole. Ropinirole exhibits the highest risk for GI AEs, Sleep/Fatigue AEs and DRs, while the risk for Cognitive AEs is higher for Pramipexole.